UNSPSC 51293011: Amineptine sodium

This classification denotes an antidepressant agent with the molecular formula C22H26NO2.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BYR55117P. European Medicines Agency schedules amineptine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00448MIG. Most nations, for tariff and trade purposes, schedule amineptine sodium under HS 29224995 and SITC 51465. As of Q4 2014, AMINEPTINE SODIUM remains US FDA's Preferred Term for this commodity.

SMILES: C1CCC2C(C1)CCC3CCCCC3C2NCCCCCCC(=O)[O-].[NA+].

UNSPSC 51293011 Amineptine sodium is a Commodity code that in practice does not align with state and local procurement activity reflected in the recent opportunities posted under it. The three recent solicitations show no substantive purchases of amineptine sodium—a tricyclic antidepressant with limited FDA approval and narrow clinical use in the United States. Instead, the opportunities reveal a significant mismatch: Seminole County, Florida is procuring naloxone and drug deactivation systems; the Texas Health and Human Services Commission is gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing statewide contracts for generic multi-source pharmaceuticals and OTC products distributed through major wholesalers. None of these solicitations targets amineptine sodium specifically. The issuing bodies span county health departments, state HHS agencies, and cooperative purchasing alliances, indicating broad participation across local and state jurisdictions, but the actual products being bought—opioid reversal agents, generic therapeutics, and OTC supplies—fall outside the code's nominal scope.

Activity under this code appears minimal or mistagged. The geographic spread includes Florida, Texas, and Minnesota, but these represent misdirected or peripheral coding rather than sustained demand for amineptine sodium. The recent opportunities—Seminole County's IFB for naloxone (due Jul 26, 2023), Texas HHS's RFI on direct-to-manufacturer programs (due Apr 3, 2026), and MMCAP's RFP for generic pharmaceuticals (due Mar 26, 2026)—demonstrate robust state and local pharmaceutical procurement, but none involves the target commodity. Firms pursuing this code should verify whether state and local procurement offices are actually specifying amineptine sodium in current RFPs, RFQs, or ITBs, as the recent posting patterns suggest the code may be incorrectly assigned to broader pharmaceutical supply contracts or that demand for this specific drug is negligible in state and local markets.